Skip to main content
. 2023 Mar 25;27(3):102759. doi: 10.1016/j.bjid.2023.102759

Table 5.

In vitro susceptibility of isolates of multidrug-resistant P. aeruginosa collected in six Latin American countriesa divided into two 3-year time periods 2015‒2017 and 2018‒2020.

Collection years (n) Compound Range MIC50 MIC90 CLSI Interpretationb
(µg/mL) %S %I %R
2015‒2017 (527) Amikacin 0.5 – > 32 > 32 > 32 43.5 6.3 50.3
Aztreonam 0.25 – > 128 64 > 128 7.6 13.7 78.7
Cefepime 4 – > 16 > 16 > 16 11.8 24.7 63.6
Ceftazidime 0.25 – > 128 64 > 128 15.2 6.3 78.6
Ceftazidime-avibactam 0.25 – >128 8 64 53.9 0.0 46.1
Colistin 0.12 – 8 1 2 NA 98.7 1.3
Imipenem 0.25 – >8 >8 >8 12.7 1.3 86.0
Levofloxacin 0.25 – > 8 > 8 > 8 8.3 4.0 87.7
Meropenem 0.12 – > 8 > 8 > 8 8.2 4.9 86.9
Piperacillin Tazobactam 4 – > 128 > 128 > 128 9.5 26.0 64.5
2018‒2020 (633) Amikacin ≤ 0.25 – > 64 64 > 64 34.1 7.0 58.9
Aztreonam 0.25 – > 128 32 > 128 11.5 15.6 72.8
Cefepime 4 – > 32 32 > 32 6.0 23.4 70.6
Ceftazidime 1 – > 128 64 > 128 10.6 7.6 81.8
Ceftazidime-avibactam 0.5 – > 128 16 > 64 45.3 0.0 54.7
Colistin ≤ 0.12 – > 8 1 2 NA 99.7 0.3
Imipenem 1 – > 8 > 8 > 8 12.0 4.4 83.6
Levofloxacin ≤ 0.25 – > 8 > 8 > 8 8.5 3.5 88.0
Meropenem 0.12 – > 16 > 16 > 16 9.0 6.0 85.0
Piperacillin Tazobactam ≤ 0.12 – > 64 >64 >64 4.9 30.6 64.5
a

Countries included Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.

b

S, susceptible; I, intermediate; R, resistant.